Methods and compositions for treating mild traumatic brain injury (mTBI), post-traumatic stress disorder (PTSD) or mTBI with PTSD with an empathogen and N-acetylcysteine are provided.

Methods and compositions for treating mild traumatic brain injury (mTBI), post-traumatic stress disorder (PTSD) or mTBI with PTSD with an empathogen and N-acetylcysteine are provided.

Methods and compositions for treating mild traumatic brain injury (mTBI), post-traumatic stress disorder (PTSD) or mTBI with PTSD with an empathogen and N-acetylcysteine are provided.

A composition including R-MDMA, S-MDMA, or specific (not 1:1 as in racemic MDMA) combinations of these two enantiomers of racemic MDMA as well as R-MDA, S-MDA, and a combination that is not 1:1 of R-MDA and S-MDA. A method of treating an individual, especially in substance-assisted psychotherapy by administering the composition to the individual. A method of personalized medicine, by evaluating an individual who is in need of MDMA treatment and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment, and administering the composition to the individual. A method of reducing abuse of MDMA by an individual, by administering R-MDMA to the individual and thereby reducing abuse.

Disclosed herein are compositions, devices and methods employing therapeutic concentrations of psilocybin, LSD or MDMA for the treatment of certain health conditions, including depression, anxiety, post-traumatic stress disorder, migraine and cluster headache. Also described are methods and apparatuses to deliver psilocybin, LSD or MDMA by intracutaneous administration via microneedle administration.

Disclosed herein are compositions, devices and methods employing therapeutic concentrations of psilocybin, LSD or MDMA for the treatment of certain health conditions, including depression, anxiety, post-traumatic stress disorder, migraine and cluster headache. Also described are methods and apparatuses to deliver psilocybin, LSD or MDMA by intracutaneous administration via microneedle administration.

The present invention features a method of reducing tactile dysfunction or anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett Syndrome, or Fragile X syndrome by administering a GABA.sub.A agent having reduced blood brain barrier or by expressing a nucleic acid encoding an exogenous alpha or beta subunit of a GABA.sub.A receptor in dorsal root ganglion neurons in the subject using a vector.

The present invention features a method of reducing tactile dysfunction or anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett Syndrome, or Fragile X syndrome by administering a GABA.sub.A agent having reduced blood brain barrier or by expressing a nucleic acid encoding an exogenous alpha or beta subunit of a GABA.sub.A receptor in dorsal root ganglion neurons in the subject using a vector.

The present invention provides methods of treating obesity, pre-diabetes, diabetes, and/or obese breast cancer, by increasing mitochondrial metabolism by increasing the activity of uncoupling protein 1 (UCP1) in adipocytes. The disclosed methods comprise contacting an adrenergic receptor agonist with an adipocyte in which the genomic activity of estrogen receptor beta (ERβ) has been inhibited or inactivated. In certain aspects, inhibition or inactivation of the genomic activity of ERβ is achieved by contacting the adipocyte with an ERβ ligand that selectively inhibits or inactivates the ERβ genomic activity.

The present invention provides methods of treating obesity, pre-diabetes, diabetes, and/or obese breast cancer, by increasing mitochondrial metabolism by increasing the activity of uncoupling protein 1 (UCP1) in adipocytes. The disclosed methods comprise contacting an adrenergic receptor agonist with an adipocyte in which the genomic activity of estrogen receptor beta (ERβ) has been inhibited or inactivated. In certain aspects, inhibition or inactivation of the genomic activity of ERβ is achieved by contacting the adipocyte with an ERβ ligand that selectively inhibits or inactivates the ERβ genomic activity.